<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antibiotics for treatment of bacteremia due to methicillin-resistant &lt;em&gt;Staphylococcus aureus&lt;/em&gt; (MRSA) in adults&lt;sup&gt;[1-5]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antibiotics for treatment of bacteremia due to methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) in adults<sup>[1-5]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Antibiotics for treatment of bacteremia due to methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) in adults<sup>[1-5]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup> <colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug</td> <td class="subtitle1">Adult dose</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Antibiotics of choice</td> </tr> <tr> <td class="indent1">Vancomycin</td> <td> <p>Loading dose<sup>*</sup>: 20 to 35 mg/kg</p> <p>Initial maintenance dose and interval determined by <span class="nowrap_whitespace">nomogram<sup>¶</sup>;</span> typically 15 to 20 mg/kg every 8 to 12 hours for most patients with normal kidney function</p> Subsequent dose and interval adjustments based on AUC-guided (preferred) or trough-guided serum concentration <span class="nowrap_whitespace">monitoring<sup>Δ</sup></span></td> </tr> <tr> <td class="indent1">Daptomycin</td> <td>8 to 10 mg/kg IV once <span class="nowrap_whitespace">daily<sup>◊</sup></span></td> </tr> <tr> <td class="indent1">Teicoplanin (not available in the United States)</td> <td> <p>Loading dose: 6 to 12 mg/kg IV every 12 hours for 3 to 5 doses</p> Maintenance dose: 6 to 12 mg/kg IV once daily; may adjust to ensure targeted trough concentrations</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Alternative agents<sup>§</sup></td> </tr> <tr> <td class="indent1">Ceftaroline</td> <td>600 mg IV every 8 hours</td> </tr> <tr> <td class="indent1">Ceftobiprole (not available in the United States)<sup>¥</sup></td> <td>500 mg IV every 6 hours for 8 days, and every 8 hours thereafter</td> </tr> <tr> <td class="indent1">Telavancin</td> <td>10 mg/kg IV once daily</td> </tr> <tr> <td class="indent1">Linezolid</td> <td>600 mg IV (or orally) every 12 hours</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is for use in conjunction with UpToDate content on treatment of bacteremia caused by methicillin-resistant <em>Staphylococcus aureus</em> (MRSA) in the absence of endocarditis. The doses listed are intended for adult patients with normal kidney function; the doses of some of these agents must be adjusted in patients with reduced kidney function. Refer to the Lexicomp drug-specific monographs within UpToDate for dose adjustments.</div><div class="graphic_footnotes"><p>AUC: area under the 24-hour time-concentration curve; IV: intravenously.</p>
<p>* The vancomycin loading dose is based on actual body weight, rounded to the nearest 250 mg increment, and not exceeding 3000 mg. Within this range, we use a higher dose for critically ill patients.</p>
<p>¶ Refer to the UpToDate topic on vancomycin dosing for sample nomogram.</p>
<p>Δ Refer to the UpToDate topic on vancomycin dosing for discussion of AUC-guided and trough-guided vancomycin dosing.</p>
<p>◊ Daptomycin dosing for treatment of bacteremia (as approved by the US Food and Drug Administration) is 6 mg/kg IV once daily; however, because daptomycin exhibits concentration-dependent killing, we favor higher dosing of 8 to 10 mg/kg IV once daily.</p>
<p>§ Refer to UpToDate content for clinical circumstances that may warrant use of a combination regimen.</p>
¥ Dosing regimen differs from approved dosing in Canada and Europe; patients with bacteremia associated with pneumonia were excluded from clinical trial<sup>[5]</sup>.</div><div class="graphic_reference">References:
<ol>
<li>Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009; 49:177.</li>
<li>Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Ther Chemother 2006; 50:3245.</li>
<li>Lui C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:285.</li>
<li>Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus Aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</li>
<li>Holland TL, Cosgrove SE, Doernberg SB, et al. ERADICATE Study Group: Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia. N Engl J Med 2023; 389:1390.</li>
</ol></div><div id="graphicVersion">Graphic 114038 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
